The current and projected economic burden of Parkinson's disease in the United States
- PMID: 23436720
- DOI: 10.1002/mds.25292
The current and projected economic burden of Parkinson's disease in the United States
Abstract
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. A lack of treatment options for changing the trajectory of disease progression, in combination with an increasing elderly population, portends a rising economic burden on patients and payers. This study combined information from nationally representative surveys to create a burden of PD model. The model estimates disease prevalence, excess healthcare use and medical costs, and nonmedical costs for each demographic group defined by age and sex. Estimated prevalence rates and costs were applied to the U.S. Census Bureau's 2010 to 2050 population data to estimate current and projected burden based on changing demographics. We estimate that approximately 630,000 people in the United States had diagnosed PD in 2010, with diagnosed prevalence likely to double by 2040. The national economic burden of PD exceeds $14.4 billion in 2010 (approximately $22,800 per patient). The population with PD incurred medical expenses of approximately $14 billion in 2010, $8.1 billion higher ($12,800 per capita) than expected for a similar population without PD. Indirect costs (e.g., reduced employment) are conservatively estimated at $6.3 billion (or close to $10,000 per person with PD). The burden of chronic conditions such as PD is projected to grow substantially over the next few decades as the size of the elderly population grows. Such projections give impetus to the need for innovative new treatments to prevent, delay onset, or alleviate symptoms of PD and other similar diseases.
Copyright © 2012 Movement Disorders Society.
Similar articles
-
Burden of illness in Parkinson's disease.Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609. Mov Disord. 2005. PMID: 16007641
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Drug and treatment costs in Parkinson's disease patients in Sweden.Acta Neurol Scand. 2012 Feb;125(2):142-7. doi: 10.1111/j.1600-0404.2011.01517.x. Epub 2011 Apr 6. Acta Neurol Scand. 2012. PMID: 21470194
-
Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.Mov Disord. 2006 Mar;21(3):362-72. doi: 10.1002/mds.20727. Mov Disord. 2006. PMID: 16211621
-
Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.Am J Manag Care. 2010 Mar;16 Suppl Implications:S87-93. Am J Manag Care. 2010. PMID: 20297871 Review.
Cited by
-
Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease.Antioxid Redox Signal. 2016 Dec 20;25(18):967-982. doi: 10.1089/ars.2015.6598. Epub 2016 Jun 27. Antioxid Redox Signal. 2016. PMID: 27224303 Free PMC article.
-
Association between use of ß2-adrenergic receptor agonists and incidence of Parkinson's disease: Retrospective cohort analysis.PLoS One. 2022 Nov 28;17(11):e0276368. doi: 10.1371/journal.pone.0276368. eCollection 2022. PLoS One. 2022. PMID: 36441791 Free PMC article.
-
Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.Mov Disord. 2022 Dec;37(12):2376-2385. doi: 10.1002/mds.29205. Epub 2022 Aug 29. Mov Disord. 2022. PMID: 36054665 Free PMC article.
-
Gender differences in the adverse events' profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis.Drug Des Devel Ther. 2016 Sep 13;10:2917-2927. doi: 10.2147/DDDT.S97088. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27695289 Free PMC article.
-
Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.J Mol Neurosci. 2015 Sep;57(1):48-62. doi: 10.1007/s12031-015-0576-8. Epub 2015 May 17. J Mol Neurosci. 2015. PMID: 25982926
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical